drugset / Trial / NCT02174627

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

NCT02174627

Phase 3 Completed 2781 enrolled AstraZeneca Kyntra Bio · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the safety and efficacy of roxadustat for treatment of anemia in patients with chronic kidney disease not on dialysis

Timeline

Start
2014-06-26
Primary completion
2018-10-04
Completion
2018-10-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Roxadustat Small molecule 70 mg Oral

Indications